Importantly, this signature was significantly downregulated in patient tumours with BRAF-mutant status compared with BRAF wild-type counterparts, right-sided vs left-sided location, and the CRC consensus molecular subtype (CMS) 1 (enriched for MSI and inflammatory/immune gene expression) vs CMS2 (enriched for genes associated with canonical Wnt signalling; Fig. 1g)36. This evidence concerns the gene BRAF and neoplasm.